Table 2.
Therapeutic effects 3 months after the procedure
| Patient number | Age, years | Gender | Pathological types | Liver lesions, b | Metastasis to other organs before chemoembolization | Embolizations, n | Effect |
|---|---|---|---|---|---|---|---|
| 1 |
80 |
Male |
Intermediately differentiated |
2 |
No |
1 |
PR |
| 2 |
72 |
Female |
Poorly differentiated |
1 |
No |
2 |
PR |
| 3 |
67 |
Female |
Intermediately differentiated |
1 |
Lung |
2 |
SD |
| 4 |
58 |
Male |
Intermediately differentiated |
> 5 |
No |
1 |
PR |
| 5 |
60 |
Female |
Intermediately differentiated |
2 |
No |
2 |
CR |
| 6 |
56 |
Male |
Intermediately differentiated |
1 |
No |
1 |
PR |
| 7 |
73 |
Female |
Poorly differentiated |
> 5 |
Abdominal lymph node |
2 |
PR |
| 8 |
54 |
Male |
Poorly differentiated |
> 5 |
Lung |
2 |
PR |
| 9 |
50 |
Female |
Poorly differentiated |
> 5 |
Abdominal lymph node |
1 |
SD |
| 10 |
78 |
Male |
Intermediately differentiated |
> 5 |
Abdominal lymph node |
2 |
PR |
| 11 |
68 |
Male |
Intermediately differentiated |
> 5 |
No |
1 |
PR |
| 12 |
64 |
Male |
Well differentiated |
1 |
No |
1 |
PR |
| 13 |
69 |
Female |
Intermediately differentiated |
1 |
Abdominal lymph node |
2 |
PR |
| 14 |
68 |
Male |
Intermediately differentiated |
> 5 |
Abdominal lymph node |
1 |
PR |
| 15 | 65 | Female | Poorly differentiated | > 5 | No | 1 | SD |
CR, complete response; PR, partial response, SD: stable disease.